Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of NIDO-361 in Patients With Spinal and Bulbar Muscular Atrophy (SBMA)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 29 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Oct 2024 Planned End Date changed from 1 Aug 2025 to 1 Oct 2025.
26 Oct 2024 Planned primary completion date changed from 1 Aug 2025 to 1 Oct 2025.
22 Oct 2024 According to a Nido Biosciences media release, European Medicines Agency (EMA) has granted Orphan Drug Designation to their lead clinical candidate NIDO-361, for the treatment of Spinal and Bulbar Muscular Atrophy (SBMA), this designation is awarded as the company has completed enrollment for a phase 2 study of the drug.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com